Who are Phentolamine Ophthalmic Solution 0.75%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fexofenadine HCL and pseudoephedrine HCL, OraVerse Injectable Product, Phentolamine Opthalmic Solution 0.75%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/phentolamine-ophthalmic-solution-0-75.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Phentolamine Ophthalmic Solution 0.75% — Competitive Intelligence Brief

Phentolamine Ophthalmic Solution 0.75% (Phentolamine Ophthalmic Solution 0.75%) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-adrenergic antagonist. Area: Ophthalmology.

phase 3 Alpha-adrenergic antagonist Alpha-1 and alpha-2 adrenergic receptors Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Phentolamine Ophthalmic Solution 0.75% (Phentolamine Ophthalmic Solution 0.75%) — Ocuphire Pharma, Inc.. Phentolamine is an alpha-adrenergic antagonist that blocks norepinephrine signaling in the eye to reduce pupil dilation and improve visual function in patients with presbyopia.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Phentolamine Ophthalmic Solution 0.75% TARGET	Phentolamine Ophthalmic Solution 0.75%	Ocuphire Pharma, Inc.	phase 3	Alpha-adrenergic antagonist	Alpha-1 and alpha-2 adrenergic receptors
Fexofenadine HCL and pseudoephedrine HCL	Fexofenadine HCL and pseudoephedrine HCL	Sanofi	marketed	Antihistamine and decongestant combination	H1 receptor (fexofenadine); alpha-1 and alpha-2 adrenergic receptors (pseudoephedrine)
OraVerse Injectable Product	OraVerse Injectable Product	sara nabil	phase 3	Alpha-adrenergic antagonist	Alpha-1 and alpha-2 adrenergic receptors
Phentolamine Opthalmic Solution 0.75%	Phentolamine Opthalmic Solution 0.75%	Ocuphire Pharma, Inc.	phase 3	Alpha-adrenergic antagonist	Alpha-1 adrenergic receptor, Alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-adrenergic antagonist class)

Ocuphire Pharma, Inc. · 2 drugs in this class
sara nabil · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Phentolamine Ophthalmic Solution 0.75% — Competitive Intelligence Brief. https://druglandscape.com/ci/phentolamine-ophthalmic-solution-0-75. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab